Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda®)   Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide     Kelowna, British Columbia – June 11, 2025 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “ ...